<DOC>
	<DOC>NCT00933972</DOC>
	<brief_summary>This 4 arm study will investigate the pharmacodynamics and pharmacokinetics of RO4998452 in type 2 diabetes patients with varying degrees of renal impairment. Eligible patients will be divided into 4 groups, with normal renal function, or mild, moderate or severe renal impairment. All patients will receive a single oral dose of RO4998452 in the fasted state.The anticipated time on study treatment is &lt;3 months (single dose study)and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients, 4080 years of age; type 2 diabetes; normal renal function, or impaired but stable renal function; stable with regard to medication or treatment regimen taken for renal impairment or diabetes. patients with a renal transplant; endstage renal disease, requiring dialysis; nephrotic syndrome, or a history of nephrectomy; type 1 diabetes mellitus.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>